Skip to main content


Table 2 IC50 Concentrations for other human triple negative breast cancer cell lines.

From: Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

  BT- 549 SUM 159 HCC 1187
Gemcitabine 13.5 nM 5.27 nM 17.1 nM
UCN-01 160.8 nM 116.4 nM 230.5 nM
AZD 7762 275.2 nM 509.1 nM 307.7 nM